Sequencing of the genomes of two strains of SARS virus by researchers at the Genome Sciences Center (GSC) in Vancouver, Canada, and the Centers for Disease Control and Prevention (CDC) in Atlanta, GA, USA (published online 1 May 2003; [DOI:10.1126/science.1085952](10.1126/science.1085952), 1085953) is "a huge step forward in the fight against severe acute respiratory syndrome (SARS)", according to Caroline Astell, who led the GSC study.

Astell claims that the sequencing has paved the way for the development of better diagnostics, antivirals including neutralising antibodies, and in the longer term, a vaccine. The sequencing of more such isolates over the next 2 years is, she says, important because it will give SARS researchers a better understanding of how rapidly the sequence of this virus is changing, which will have implications for vaccine development.

It will also be of interest to identify the source of the virus. The virus must have jumped species from an animal, since a preliminary study (Ksiazek TG, et al, *N Engl J Med;* published online April 10, 2003; [DOI:10.1056/NEJMoa030781](10.1056/NEJMoa030781)) indicated that there is no evidence that the virus has infected human beings previously. The more sensitive diagnostics that are now available to identify this virus should facilitate identification of the original animal host. The sequence of this virus may also provide clues as to what mutations occurred to allow the virus to jump species, since there is prior evidence for transfer of viruses from animals to human beings---eg, swine flu and HIV.

The latest studies show that a new coronavirus is the most likely cause of SARS, as did an animal study in the Netherlands where healthy monkeys went on to develop typical SARS after infection with a coronavirus. In addition, the researchers isolated the virus from the affected organs. However, Canadian researchers who found metapneumovirus (a member of the paramyxovirus group) in many of their patients insist that most of the patients did not have a coronavirus. A similar finding came from the Prince of Wales Hospital in Hong Kong, where researchers detected meta-pneumovirus in more than 35% of SARS patients by culture. And using reverse transcriptase-PCR, they were able to detect metapneumovirus genes in several patients.

Dick Thompson, a WHO spokesperson says his agency is "looking into the issue \[of metapneumovirus\] and hopes to have it resolved soon. But this doesn\'t mean we are backing away from the coronavirus \[because\] it has been found in every lab in the network and numerous samples; indeed, we are using it as part of our diagnostic strategy and vaccine preparations, should the disease become endemic".

John Tam (Prince of Wales Hospital, Hong Kong) believes the Canadian report on low detection of coronavirus in probable SARSpatients may be due to the collection of samples early in the infection giving a lower detection rate. This, he says, can be resolved by subsequent serological examination of paired serum samples from these patients on coronavirus. However, their report on the detection of coronavirus in unexposed and symptom-free patients is "puzzling". Even more puzzling are the reports that subclinical or symptomless SARS does occur.

Although there are several new laboratory tests currently in use to detect the SARS-associated corona-virus (SARS-CoV) or antibodies, none of them has yet been validated. "Validation is on but we are talking about a time scale of months until there will be tests that are evaluated finally for clinical use. However, critical data for some tests will be available within weeks", Christian Drosten (Bernhard-Nocht Institute for Tropical Medicine, Hamburg, Germany) told *TLID.*

The problem has been further compounded by a lack of efficacious treatment regimen for SARS patients. As a result, treatment---especially in Hong Kong---mostly amounts to keeping patients isolated and treating their symptoms with steroids and antiviral drugs such as ribavirin and oseltamivir, whose efficacy in SARS remains unknown.

According to the CDC, "early information from laboratory experiments suggests that ribavirin does not inhibit virus growth or cell-to-cell spread of one isolate of the new coronavirus that was tested". Some clinicians in Hong Kong, however, continue to ignore this evidence and advocate use of ribavirin. "Due to the media hype, it is extremely difficult to carry out such trials now in Hong Kong since all patients demand it", Tam warned.
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Another issue that remains largely unresolved is the continual viral shedding by some clinically recovered SARS cases. "If such is the case for most, or even some, of the recovered SARS patients, perhaps this \[viral shedding\] may account for the ongoing transmission we are seeing in places like Singapore, in household and workplace contacts of clinically recovered SARS patients", cautions Julian Tang (University College London Hospitals, UK).

"Perhaps the laboratories of the WHO collaborating network should ask for convalescent stool samples as well as sera to monitor and characterise this phenomenon", Tang suggests as a way to counter continued transmission in convalescence.
